Thromboembolic Risk and Survival Outcomes in Multiple Myeloma Patients Following Autologous Stem Cell Transplantation
Acta Haematologica Oncologica Turcica, cilt.59, sa.2, ss.163-168, 2026 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 59 Sayı: 2
- Basım Tarihi: 2026
- Doi Numarası: 10.4274/ahot.galenos.2026.2026-6-2
- Dergi Adı: Acta Haematologica Oncologica Turcica
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.163-168
- Anahtar Kelimeler: autologous stem cell transplantation, multiple myeloma, Venous thromboembolism
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Erciyes Üniversitesi Adresli: Evet
Özet
Aim: To assess risk factors for venous thromboembolism (VTE) in patients with multiple myeloma (MM) who underwent autologous hematopoietic cell transplantation (HCT). Methods: This single-center retrospective study included 380 MM patients who underwent autologous HCT. Patients developed VTE were identified by reviewing patients’ medical data. In all patients, chemotherapy regimen, remission status, comorbid conditions, age at time of HCT, number of autologous HCTs, disease stage, follow-up duration, immunoglobulin type, and mortality were assessed, and their effects on VTE development were evaluated. Results: Of the patients included, 63.2% (n=240) were male while 36.8% (n=140) were female. VTE occurred in 40 patients (10.5%). Mean follow-up was found as 41.63±33.84 mounths. Overall, 55.8% (n=212) of the patients died after autologous HCT. A significant correlation was found between older age at the time of HCT and VTE development (p=0.046). The rate of VTE-free patients was higher in patients in remission than in those not in remission (p=0.045). Conclusion: Remission status and older age at the time of HCT increased the risk of VTE in MM patients who underwent autologous HCT. Keywords.